Caris Life Sciences, Inc. Common Stock (CAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has a cash flow conversion efficiency ratio of 0.104x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($61.35 Million) by net assets ($591.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CAI market cap overview for the company's overall valuation and market capitalisation.
Caris Life Sciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Caris Life Sciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore Caris Life Sciences, Inc. Common Stock (CAI) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Blue Owl Capital Inc
NYSE:OWL
|
0.070x |
|
CarMax Inc
NYSE:KMX
|
-0.094x |
|
Fluor Corporation
NYSE:FLR
|
0.039x |
|
Hellenic Telecommunications Organization S.A
AT:HTO
|
0.117x |
|
ASX LTD UNSPONS.ADR 1
F:AUX1
|
N/A |
|
Jiangsu Leadmicro Nano Technology Co. Ltd. A
SHG:688147
|
N/A |
|
Ringkjoebing Landbobank A/S
CO:RILBA
|
0.002x |
|
Bank of India
NSE:BANKINDIA
|
-0.530x |
Annual Cash Flow Conversion Efficiency for Caris Life Sciences, Inc. Common Stock (2005–2025)
The table below shows the annual cash flow conversion efficiency of Caris Life Sciences, Inc. Common Stock from 2005 to 2025. View Caris Life Sciences, Inc. Common Stock stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $577.31 Million | $83.16 Million | 0.144x | +46.79% |
| 2024-12-31 | $-2.50 Billion | $-245.20 Million | 0.098x | -23.77% |
| 2023-12-31 | $-2.14 Billion | $-276.10 Million | 0.129x | -23.31% |
| 2022-12-31 | $-1.70 Billion | $-285.71 Million | 0.168x | -57.45% |
| 2020-12-31 | $702.24 Million | $277.02 Million | 0.394x | +7.66% |
| 2019-12-31 | $693.24 Million | $254.00 Million | 0.366x | +42.90% |
| 2018-12-31 | $701.13 Million | $179.77 Million | 0.256x | -6.84% |
| 2017-12-31 | $563.85 Million | $155.19 Million | 0.275x | -2.58% |
| 2016-12-31 | $457.50 Million | $129.26 Million | 0.283x | -11.57% |
| 2015-12-31 | $461.26 Million | $147.37 Million | 0.319x | +1.30% |
| 2014-12-31 | $442.90 Million | $139.69 Million | 0.315x | +5.43% |
| 2013-12-31 | $415.13 Million | $124.19 Million | 0.299x | -2.87% |
| 2012-12-31 | $346.85 Million | $106.83 Million | 0.308x | +6.25% |
| 2011-12-31 | $248.74 Million | $72.11 Million | 0.290x | +35.07% |
| 2010-12-31 | $197.67 Million | $42.42 Million | 0.215x | -10.04% |
| 2009-12-31 | $129.10 Million | $30.80 Million | 0.239x | -1.06% |
| 2008-12-31 | $113.79 Million | $27.44 Million | 0.241x | +11988.54% |
| 2007-12-31 | $131.15 Million | $-266.00K | -0.002x | -100.67% |
| 2006-12-31 | $27.75 Million | $8.38 Million | 0.302x | -66.15% |
| 2005-12-31 | $32.99 Million | $29.41 Million | 0.891x | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more